Sanofi has secured U.S. FDA approval for Wayrilz (rilzabrutinib), marking the first Bruton’s tyrosine kinase (BTK) inhibitor approved for adults with persistent or chronic immune thrombocytopenia (ITP) who have shown insufficient response to prior therapies. This approval is based on the pivotal LUNA 3 phase 3 study, which demonstrated rapid, durable platelet responses and improvements in multiple ITP symptoms, highlighting Wayrilz’s potential to address the complex immune dysregulation underlying the disease.

Science Significance

WIDAPLIK combines telmisartan, amlodipine, and indapamide in a single tablet, offering a multi-mechanism approach to lower blood pressure. By incorporating two lower-dose options than existing combinations, it is designed to optimize efficacy while maintaining a well-established safety profile, potentially improving adherence and patient outcomes in hypertension management.

Regulatory Significance

Wayrilz received Fast Track and Orphan Drug Designations (ODD) from the FDA for ITP, with additional orphan designations in Japan and the EU, as well as ODD for warm autoimmune hemolytic anemia, IgG4-related disease, and sickle cell disease. This demonstrates Sanofi’s strategic execution of global regulatory pathways to accelerate patient access to rare disease therapies.

Business Significance

Wayrilz expands Sanofi’s specialty care portfolio in rare and immunological diseases. With an estimated 25,000 U.S. adults eligible, supported by the HemAssist patient program for insurance and financial navigation, Wayrilz represents both a clinically differentiated and commercially promising therapy.

Patients’ Significance

Wayrilz offers a meaningful new option to reduce the physical and emotional burdens of ITP. LUNA 3 reported a 10.6-point improvement in quality-of-life measures, including fatigue, cognitive function, and daily living impacts, underscoring the therapy’s potential to enhance real-world outcomes for those unresponsive to standard treatments.

Policy Significance

The approval reinforces the FDA’s commitment to advancing innovative treatments for rare and complex disorders, highlighting how regulatory incentives, scientific innovation, and patient support programs can converge to address unmet medical needs.

Transaction Highlights

The transition from clinical research to commercial availability is already underway: Wayrilz was approved in the UAE in June 2025, and regulatory submissions are ongoing in the EU and China, setting the stage for broader global adoption of this first-in-class BTK inhibitor for ITP.

Source: Sanofi Press Release